Epoetin Alfa in Treating Cancer-Related Anemia in Patients With Non-Myeloid Cancer Who Are Not Currently Receiving Chemotherapy or Radiation Therapy
Recruitment status was Active, not recruiting
RATIONALE: Epoetin alfa may stimulate red blood cell production and treat anemia in patients with non-myeloid cancer.
PURPOSE: This clinical trial is studying how well epoetin alfa works in treating cancer-related anemia in patients with non-myeloid cancer who are not currently receiving chemotherapy or radiation therapy.
Multiple Myeloma and Plasma Cell Neoplasm
Unspecified Adult Solid Tumor, Protocol Specific
Biological: epoetin alfa
|Study Design:||Masking: Open Label
Primary Purpose: Supportive Care
|Official Title:||A Pilot Study To Evaluate The Response Rate Of Procrit (Epoetin Alfa) At 60,000 Units Every Two Weeks In Anemic Patients With Cancer Not Receiving Chemotherapy Or Radiation Therapy|
|Study Start Date:||July 2004|
- Determine the efficacy of epoetin alfa, in terms of hematologic response, in patients with non-myeloid malignancy and cancer-related anemia who are not currently receiving chemotherapy or radiotherapy.
- Determine time to hematologic response in patients treated with this drug.
- Determine transfusion requirements in patients treated with this drug.
- Determine the safety and tolerability of this drug in these patients.
- Determine the quality of life of patients treated with this drug.
OUTLINE: This is an open-label, nonrandomized, pilot, multicenter study.
Patients receive epoetin alfa subcutaneously on day 1 of weeks 1, 3, 5, 7, 9, and 11 in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline and then at weeks 5, 9, 13, and 17.
Patients are followed for 4 weeks.
PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study.
|United States, California|
|Jonsson Comprehensive Cancer Center, UCLA|
|Los Angeles, California, United States, 90095-6996|
|Study Chair:||John A. Glaspy, MD, MPH||Jonsson Comprehensive Cancer Center|